Where does Xenon Pharmaceuticals's cash flow data come from?

Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$383.17M-10.8%	-$345.91M-12.9%	-$306.33M-10.1%	-$278.23M-10.7%	-$251.45M-7.3%
Depreciation and amortization	$2.47M-2.8%	$2.54M-2.1%	$2.6M-1.0%	$2.62M-0.3%	$2.63M+2.9%
Stock-based compensation	$58.43M+8.8%	$53.71M+1.0%	$53.19M+1.3%	$52.49M-1.9%	$53.49M+5.5%
Deferred income taxes	-$1.54M+51.9%	-$3.2M+70.1%	-$10.7M-3.7%	-$10.32M+1.6%	-$10.48M-18.2%
Change in accounts payable	$7.49M+36.0%	$5.51M-35.2%	$8.5M—	——	——
Change in other assets	——	——	$12.01M+56.4%	$7.68M+521%	$1.24M+25.7%
Change in other liabilities	——	——	——	——	——
Non-cash operating lease expense	$1.33M+1.2%	$1.31M+1.2%	$1.3M+1.2%	$1.28M+1.3%	$1.27M+1.0%
Change in operating lease liabilities	-$1.34M-3.2%	-$1.3M-1.3%	-$1.28M-1.9%	-$1.26M-2.0%	-$1.23M-0.9%
Change in receivables	——	——	-$116K-146%	$250K-96.8%	$7.83M+1,175%
Net cash from operating activities	-$306.36M-9.8%	-$279.12M-10.8%	-$252.02M-9.6%	-$229.94M-16.8%	-$196.85M-8.5%
Capital expenditures	$889K+11.3%	$799K-36.8%	$1.26M-19.6%	$1.57M-46.3%	$2.93M-4.7%
Net cash from investing activities	-$223.79M-203%	$218M-14.1%	$253.8M+17.6%	$215.77M-11.1%	$242.7M+47.1%
Proceeds from issuance of common stock	$9.3M+87.4%	$4.96M+37.0%	$3.62M+187%	$1.26M+5.4%	$1.2M+2,449%
Net cash from financing activities	$958.98M+719%	$117.11M+646%	$15.71M+17.7%	$13.35M+0.5%	$13.28M+9.5%
Effect of exchange rate changes on cash	——	——	——	-$589K+58.6%	-$1.42M+17.6%
Net increase (decrease) in cash	$429.21M+660%	$56.45M—	——	——	——
Income taxes paid	——	——	——	——	——
Unrealized Gain (Loss), Foreign Currency Transaction, before Tax	$313K+529%	-$73K+84.6%	-$475K+20.7%	-$599K+35.1%	-$923K-23.9%
Operating lease liabilities	-$1.34M-3.2%	-$1.3M-1.3%	-$1.28M-1.9%	-$1.26M-2.0%	-$1.23M-0.9%
Increase (Decrease) in Other Receivables	——	——	-$116K-146%	$250K—	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$12.01M+56.4%	$7.68M+521%	$1.24M+25.7%
Operating lease right-of-use asset amortization	$1.33M+1.2%	$1.31M+1.2%	$1.3M+1.2%	$1.28M+1.3%	$1.27M+1.0%
Net proceeds from sales of subsidiary shares	——	——	——	——	——
Proceeds From Offerings Net	$921.64M+722%	$112.15M+28.7%	$87.13M+40.3%	$62.12M+67.4%	$37.1M+207%
Fair Value Of Stock Options And Warrants Exercised On A Cashless Basis	——	$21M+17.8%	$17.82M+21.7%	$14.65M+27.6%	$11.48M+38.2%
Fair Value Of Stock Options Exercised On Cashless Basis	——	——	$15.43M+6.1%	$14.55M+86.4%	$7.8M-6.0%
Increase Decrease In Operating Lease Liability	-$1.34M-3.2%	-$1.3M-1.3%	-$1.28M-1.9%	-$1.26M-2.0%	-$1.23M-0.9%
Operating Lease Payments	$1.73M+1.1%	$1.71M+0.4%	$1.71M+0.5%	$1.7M+1.0%	$1.68M+0.5%
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	——
Free cash flow	-$307.25M-9.8%	-$279.92M-10.5%	-$253.29M-9.4%	-$231.51M-15.9%	-$199.78M-8.3%
Free cash flow	-$307.25M-9.8%	-$279.92M-10.5%	-$253.29M-9.4%	-$231.51M-15.9%	-$199.78M-8.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Xenon Pharmaceuticals's cash flow data come from?: Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.